Articles > New & Newsworthy

Executives of the Big Three pharma companies involved in diabetes research, development, and manufacturing — Eli Lilly and Co., Novo Nordisk, and Sanofi — spoke publicly this week at JPMorgan’s 2020 Healthcare conference on issues related to insulin pricing and supply.

Tandem t:slim X 2 pump with control IQ technology

Last month, the FDA approved the Tandem Diabetes Care update to its t:slim X2 insulin pump Control-IQ technology, clearing the way for the first automated and interoperable insulin dosing system on the U.S. market.

Fiasp fast acting insulin pen

The U.S. Food and Drug Administration has approved Novo Nordisk's fast-acting Fiasp insulin for use in children as well as adults, the pharmaceutical firm announced Monday.

A patient loads insulin for his routine shot.

At least 17 states have passed laws carving out exceptions for pharmacists to fill insulin prescriptions during emergency situations. These legal reforms are seen by some advocates as the first real sign of progress for improved access to insulin in the United States.

logo for French pharma manufacturer Sanofi

Sanofi, the French pharmaceutical giant which manufactures the long-acting insulin Lantus, announced Monday that it would no longer be investing in research for new drugs to treat diabetes. The manufacturer also told investors it would no longer be investigating new treatments for cardiovascular health. “To be out of cardiovascular and diabetes is not easy for …

Two airline pilots monitoring instruments

The FAA is moving to allow pilots with type 1 diabetes to take command of U.S.-based commercial flights, reports CNN.

Omnipod with app.

Insulet will now be able to market their continuous insulin delivery system as an integrated insulin pump.

Researchers have discovered that an increase of a particular type of microRNA in the bloodstream appears to herald the onset of type 1 diabetes.

Such a technique might one day help researchers devise treatments to cause dormant cells to begin to create insulin again. More research will be needed to validate this preliminary effort, however.

If approved, it could have the potential to reshape how severe hypoglycemia is treated.